Methylation of Sprouty-4 (SPRY4), an inhibitor of the receptor-transduced mitogen-activated protein kinase (MAPK) signalling pathway, has been detected in prostate cancer [42]. This evidence concerns the gene SPRY4 and prostate carcinoma.